real-time news and commentary for investors
Monday, Jul 8
Novartis' (NVS) secukinumab drug was better at clearing skin in patients with moderate-to-severe...
Novartis' (NVS) secukinumab drug was better at clearing skin in patients with moderate-to-severe plaque psoriasis than Amgen's (AMGN) Enbrel in a Phase III trial in which secukinumab met all its primary and secondary targets. Plaque psoriasis is a painful skin condition characterized by itching and scaling, and it affects 125M people. (PR) Meanwhile, NICE, the U.K.'s health-cost regulator, won't recommend using Novartis' Afinitor drug to treat breast cancer even though it's approved for the indication in the EU and U.S.